Skip to main content
Top

Open Access 05-03-2025 | Postmenopause | Original Article

Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women

Authors: Bingru Lu, Qunxiao Han, Shiyu Zhao, Shan Ding, Guolin Bao, Yiqing Liu

Published in: Journal of Bone and Mineral Metabolism

Login to get access

Abstract

Introduction

To explore the associations between hormones, metabolic markers, and low bone mass in perimenopausal and postmenopausal women.

Materials and methods

A total of 198 women were enrolled in this study. The correlations between hormones, metabolic markers, and BMD were analyzed. Risk factors for bone loss were identified. Receiver operating characteristic (ROC) curves were used to display the predictive power of these risk factors.

Results

The years since menopause and the levels of glucose (GLU), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were inversely correlated with BMD, while estrogen and testosterone were positively correlated with BMD. Age (odds ratio [OR] 1.232; 95% confidence interval [CI] 1.106–1.372; p < 0.001), GLU (OR 1.848; 95% CI 1.116–3.059; p = 0.017), and FSH (OR 1.089; 95% CI 1.003–1.182; p = 0.042) were identified as risk factors for bone loss. Age (AUC = 0.884, 95% CI 0.833–0.935), FSH (AUC = 0.824, 95% CI 0.760–0.888), and GLU (AUC = 0.683, 95% CI 0.599–0.768) demonstrated significant discrimination capability for bone loss. The combined application of these factors resulted in a better prediction effect (AUC = 0.930, 95% CI 0.893–0.967).

Conclusions

Age, FSH, and GLU were found to be specific risk factors for bone loss. The utilization of these factors offers compelling predictive power for bone loss in perimenopausal and postmenopausal women.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am 50:167–178CrossRefPubMed Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am 50:167–178CrossRefPubMed
3.
go back to reference Krishnan A, Muthusami S (2017) Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol 232:R99–R113CrossRefPubMed Krishnan A, Muthusami S (2017) Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol 232:R99–R113CrossRefPubMed
4.
go back to reference Cipriani C, Colangelo L, Santori R, Renella M, Mastrantonio M et al (2020) The interplay between bone and glucose metabolism. Front Endocrinol (Lausanne) 11:122CrossRefPubMed Cipriani C, Colangelo L, Santori R, Renella M, Mastrantonio M et al (2020) The interplay between bone and glucose metabolism. Front Endocrinol (Lausanne) 11:122CrossRefPubMed
5.
go back to reference Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA et al (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRefPubMed Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA et al (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRefPubMed
6.
go back to reference Khosla S, Monroe DG (2018) Regulation of bone metabolism by sex steroids. Cold Spring Harb Perspect Med 8(1):a031211 Khosla S, Monroe DG (2018) Regulation of bone metabolism by sex steroids. Cold Spring Harb Perspect Med 8(1):a031211
7.
go back to reference Foger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P (2020) Osteoporosis: pathophysiology and therapeutic options. EXCLI J 19:1017–1037PubMedPubMedCentral Foger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P (2020) Osteoporosis: pathophysiology and therapeutic options. EXCLI J 19:1017–1037PubMedPubMedCentral
10.
go back to reference Sowers MR, Finkelstein JS, Ettinger B, Bondarenko I, Neer RM et al (2003) The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 14:44–52CrossRefPubMed Sowers MR, Finkelstein JS, Ettinger B, Bondarenko I, Neer RM et al (2003) The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 14:44–52CrossRefPubMed
11.
go back to reference Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35–43CrossRefPubMed Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35–43CrossRefPubMed
12.
go back to reference Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640–1646CrossRefPubMed Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640–1646CrossRefPubMed
13.
go back to reference Kan B, Zhao Q, Wang L, Xue S, Cai H, Yang S (2021) Association between lipid biomarkers and osteoporosis: a cross-sectional study. BMC Musculoskelet Disord 22:759CrossRefPubMedPubMedCentral Kan B, Zhao Q, Wang L, Xue S, Cai H, Yang S (2021) Association between lipid biomarkers and osteoporosis: a cross-sectional study. BMC Musculoskelet Disord 22:759CrossRefPubMedPubMedCentral
15.
go back to reference Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T et al (2013) HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A 110:16568–16573CrossRefPubMedPubMedCentral Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T et al (2013) HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A 110:16568–16573CrossRefPubMedPubMedCentral
17.
18.
20.
go back to reference Gourlay ML, Preisser JS, Hammett-Stabler CA, Renner JB, Rubin J (2011) Follicle-stimulating hormone and bioavailable estradiol are less important than weight and race in determining bone density in younger postmenopausal women. Osteoporos Int 22:2699–2708CrossRefPubMed Gourlay ML, Preisser JS, Hammett-Stabler CA, Renner JB, Rubin J (2011) Follicle-stimulating hormone and bioavailable estradiol are less important than weight and race in determining bone density in younger postmenopausal women. Osteoporos Int 22:2699–2708CrossRefPubMed
21.
go back to reference Gourlay ML, Specker BL, Li C, Hammett-Stabler CA, Renner JB, Rubin JE (2012) Follicle-stimulating hormone is independently associated with lean mass but not BMD in younger postmenopausal women. Bone 50:311–316CrossRefPubMed Gourlay ML, Specker BL, Li C, Hammett-Stabler CA, Renner JB, Rubin JE (2012) Follicle-stimulating hormone is independently associated with lean mass but not BMD in younger postmenopausal women. Bone 50:311–316CrossRefPubMed
22.
go back to reference Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed
23.
go back to reference Hall JE (2007) Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 25:344–351CrossRefPubMed Hall JE (2007) Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 25:344–351CrossRefPubMed
24.
go back to reference Kupai K, Kang HL, Posa A, Csonka A, Varkonyi T, Valkusz Z (2024) Bone loss in diabetes mellitus: diaporosis. Int J Mol Sci 25:7269 Kupai K, Kang HL, Posa A, Csonka A, Varkonyi T, Valkusz Z (2024) Bone loss in diabetes mellitus: diaporosis. Int J Mol Sci 25:7269
25.
go back to reference Palui R, Pramanik S, Mondal S, Ray S (2021) Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes 12:706–729CrossRefPubMedPubMedCentral Palui R, Pramanik S, Mondal S, Ray S (2021) Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes 12:706–729CrossRefPubMedPubMedCentral
26.
go back to reference Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y et al (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22:17–23CrossRefPubMed Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y et al (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22:17–23CrossRefPubMed
27.
go back to reference McCarthy AD, Etcheverry SB, Cortizo AM (2001) Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 38:113–122CrossRefPubMed McCarthy AD, Etcheverry SB, Cortizo AM (2001) Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 38:113–122CrossRefPubMed
28.
go back to reference Keats EC, Dominguez JM 2nd, Grant MB, Khan ZA (2014) Switch from canonical to noncanonical Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells 32:1649–1660CrossRefPubMed Keats EC, Dominguez JM 2nd, Grant MB, Khan ZA (2014) Switch from canonical to noncanonical Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells 32:1649–1660CrossRefPubMed
29.
go back to reference Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS et al (2013) Marrow fat and bone–new perspectives. J Clin Endocrinol Metab 98:935–945CrossRefPubMedPubMedCentral Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS et al (2013) Marrow fat and bone–new perspectives. J Clin Endocrinol Metab 98:935–945CrossRefPubMedPubMedCentral
30.
go back to reference Liu LF, Shen WJ, Zhang ZH, Wang LJ, Kraemer FB (2010) Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARgamma and adiponectin. J Cell Physiol 225:837–845CrossRefPubMed Liu LF, Shen WJ, Zhang ZH, Wang LJ, Kraemer FB (2010) Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARgamma and adiponectin. J Cell Physiol 225:837–845CrossRefPubMed
31.
go back to reference Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T (2015) Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun 461:193–199CrossRefPubMed Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T (2015) Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun 461:193–199CrossRefPubMed
32.
go back to reference Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295–303CrossRefPubMed Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295–303CrossRefPubMed
33.
go back to reference Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W (2005) Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 28:2850–2855CrossRefPubMed Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W (2005) Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 28:2850–2855CrossRefPubMed
34.
go back to reference Park SK, Jung JY, Oh CM, Choi JM, Kim MH et al (2021) Fasting glucose level and the risk of incident osteoporosis in the Koreans. Bone 142:115690CrossRefPubMed Park SK, Jung JY, Oh CM, Choi JM, Kim MH et al (2021) Fasting glucose level and the risk of incident osteoporosis in the Koreans. Bone 142:115690CrossRefPubMed
Metadata
Title
Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women
Authors
Bingru Lu
Qunxiao Han
Shiyu Zhao
Shan Ding
Guolin Bao
Yiqing Liu
Publication date
05-03-2025
Publisher
Springer Nature Singapore
Published in
Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-025-01595-x

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video